Shares of China Biologic Products, Inc. (NASDAQ:CBPO) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price objective of $131.67 for the company and are forecasting that the company will post $1.32 EPS for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 111 out of 265 based on the ratings given to its competitors.

CBPO has been the topic of a number of recent research reports. BidaskClub lowered China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Goldman Sachs Group, Inc. (The) initiated coverage on China Biologic Products in a report on Tuesday, May 30th. They issued a “neutral” rating on the stock. Zacks Investment Research lowered China Biologic Products from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $140.00 target price on shares of China Biologic Products in a report on Monday, June 12th.

COPYRIGHT VIOLATION WARNING: “Zacks: China Biologic Products, Inc. (CBPO) Given Consensus Rating of “Strong Buy” by Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/18/zacks-china-biologic-products-inc-cbpo-given-consensus-rating-of-strong-buy-by-analysts.html.

China Biologic Products (NASDAQ:CBPO) traded up 0.75% during midday trading on Friday, reaching $89.97. The company’s stock had a trading volume of 703,150 shares. The firm has a 50 day moving average of $100.00 and a 200 day moving average of $106.80. China Biologic Products has a 52-week low of $88.25 and a 52-week high of $127.36. The firm has a market cap of $2.45 billion, a P/E ratio of 23.42 and a beta of 1.70.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The company had revenue of $89.28 million for the quarter, compared to analyst estimates of $97.33 million. During the same quarter last year, the company earned $1.26 earnings per share. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. Analysts anticipate that China Biologic Products will post $4.95 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of CBPO. BlackRock Inc. raised its stake in shares of China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after buying an additional 1,318,183 shares during the period. UBS Asset Management Americas Inc. raised its stake in shares of China Biologic Products by 9.3% in the first quarter. UBS Asset Management Americas Inc. now owns 198,220 shares of the biopharmaceutical company’s stock worth $19,848,000 after buying an additional 16,933 shares during the period. Bank of America Corp DE raised its stake in shares of China Biologic Products by 67.3% in the first quarter. Bank of America Corp DE now owns 56,118 shares of the biopharmaceutical company’s stock worth $5,619,000 after buying an additional 22,583 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of China Biologic Products by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 58,559 shares of the biopharmaceutical company’s stock worth $5,863,000 after buying an additional 5,091 shares during the period. Finally, Nomura Holdings Inc. acquired a new stake in shares of China Biologic Products during the first quarter worth approximately $463,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About China Biologic Products

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.